IL20: Interleukin-20
Pro-inflammatory and angiogenic cytokine mainly secreted by monocytes and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on IL20, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Fletikumab | Phase 2 | Novo Nordisk | Antibody | InhibitorInterleukin-20 inhibitor | 0 |
- Pathologic fracture0.20
- Rheumatoid arthritis0.13
- Neoplasm0.11
- Psoriasis0.10
- Psoriatic arthritis0.09
- Osteoarthritis0.09
- Hepatocellular carcinoma0.08
- Colitis0.08
- Atopic eczema0.08
- Diabetes mellitus0.08
- Chronic obstructive pulmonary disease0.08
- Diabetic kidney disease0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713449, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9NYY1, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets